Evidence for Improved Quality of Life Among Chronic Pancreatitis Patients Undergoing Total Pancreatectomy with Islet Autotransplantation Using EORTC QLQ-C30 and QLQ-PAN 26
Baylor University Medical Center, Dallas, TX
Meeting: 2022 American Transplant Congress
Abstract number: 1186
Keywords: Islets, Pancreas, Pancreatitis, Quality of life
Topic: Clinical Science » Pancreas » 65 - Pancreas and Islet: All Topics
Session Information
Session Name: Pancreas and Islet: All Topics
Session Type: Poster Abstract
Date: Sunday, June 5, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: Total pancreatectomy with islet autotransplantation (TPIAT) is the treatment of choice to preserve endocrine function, alleviate pain, reduce or eliminate chronic narcotic use and improve a very poor-quality life when other strategies were not effective in chronic pancreatitis. We reviewed Quality of Life using a large cohort of TPIAT patients at our center.
*Methods: Two quality of life surveys, EORTC QLQ-C30 and QLQ-PAN 26, were administered in a prospective cohort study of 116 patients between 2011 to 2021 with pre-and postoperative, and during regularly scheduled follow-up. The mean age was 41 years, 35% were male, mean BMI was 26.39 ± 5.78. All clinical data were recorded for each patient.
*Results: Mean transplant islet dose was 5,152.05 ± 2,945.7 islet equivalent/kg patient weight. At 1 and 2 year after TPIAT, HbA1c was 7.25 % ± 1.97 and 7.27 % ± 2.42 respectively (5.95 % ± 1.13 pre-TPIAT). Mean morphine dose after 1 and 2 years was 44.16 ± 92.71 and 42.12 ± 67.52 respectively (pre-TPIAT 117.83 ± 137.67). Mean insulin use (unit/day) at preop was 2.15 ± 8.04, at 1 and 2-year was 14.65 ± 15.02 and 15.49 ± 15.87. Of 116 patients with pre-operative survey, 53 and 31 completed 1-year and 2-year follow-up respectively. TPIAT EORTC QlQ-C30 patients experienced a significant improvement from pre-op in all functional dimensions: physical functioning (p=0.026), role function (p<0.001), emotional function (p=0.010), cognitive functioning (p<0.001), social functioning (p=0.007); and a significantly reduction from pre-op in symptom dimensions: fatigue (p<0.001), nausea and vomiting (p=0.004), pain(p<0.001), insomnia (p=0.002), appetite loss (p<0.001), constipation (p=0.032). The global score increased (p-=0.001). EORTC-PAN26 patients reported a significantly lower pancreatic pain (p<0.001), bloating score (p=0.003), digestive symptoms (p<0.001), taste score (p<0.007), indigestion score (p=0.002), weight loss (p=0.003), body image (p=0.017), sexuality (p=0.013).
*Conclusions: Our current QoL survey results strongly support the improvement in quality of life in chronic pancreatitis after TPIAT.
To cite this abstract in AMA style:
Coluzzi M, Naziruddin B, Saracino G, Testa G, Beecherl E, Onaca N. Evidence for Improved Quality of Life Among Chronic Pancreatitis Patients Undergoing Total Pancreatectomy with Islet Autotransplantation Using EORTC QLQ-C30 and QLQ-PAN 26 [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/evidence-for-improved-quality-of-life-among-chronic-pancreatitis-patients-undergoing-total-pancreatectomy-with-islet-autotransplantation-using-eortc-qlq-c30-and-qlq-pan-26/. Accessed May 30, 2025.« Back to 2022 American Transplant Congress